NUVB vs. SLN, ANAB, YMAB, SVRA, IRON, PHAR, PAHC, DNTH, SIGA, and EOLS
Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Silence Therapeutics (SLN), AnaptysBio (ANAB), Y-mAbs Therapeutics (YMAB), Savara (SVRA), Disc Medicine (IRON), Pharming Group (PHAR), Phibro Animal Health (PAHC), Dianthus Therapeutics (DNTH), SIGA Technologies (SIGA), and Evolus (EOLS). These companies are all part of the "pharmaceutical preparations" industry.
Silence Therapeutics (NASDAQ:SLN) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
Silence Therapeutics presently has a consensus target price of $57.25, indicating a potential upside of 158.00%. Nuvation Bio has a consensus target price of $6.60, indicating a potential upside of 106.90%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Silence Therapeutics is more favorable than Nuvation Bio.
Silence Therapeutics has higher revenue and earnings than Nuvation Bio. Silence Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Silence Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
In the previous week, Nuvation Bio had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Nuvation Bio and 0 mentions for Silence Therapeutics. Nuvation Bio's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 36.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Nuvation Bio received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Nuvation Bio an outperform vote while only 70.00% of users gave Silence Therapeutics an outperform vote.
Nuvation Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -171.41%. Silence Therapeutics' return on equity of -12.21% beat Nuvation Bio's return on equity.
Summary
Nuvation Bio beats Silence Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Nuvation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvation Bio Competitors List
Related Companies and Tools
